Chan Sing En appointed independent director at Singapore subsidiary

Management Changes View source PDF Explain this filing

FISCHER · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-9.0%Reaction day

₹27.74

prior close

₹25.76

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.7%-10.8% vs market

Medical Equipment & Supplies peers, median of 13sector+0.3%-9.4% vs sector

On the reaction day the stock moved 10.8 pts less than Nifty Microcap 250 and 9.4 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.4

15m

-0.2

30m

-1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-9.0+1.7-10.8+0.3-9.4

Next day

-5.0pendingpending+2.4-7.4

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

On October 27, 2026, Fischer Medical Ventures appointed Mr. Chan Sing En as an independent director of FMV Global Innovations Pte. Ltd., its material wholly owned subsidiary in Singapore. Chan has over 30 years of experience in private equity, corporate finance and operational turnarounds. He is not related to the company's directors and is not debarred from holding director positions.

Likely market impact

The appointment may strengthen oversight and financial expertise at a key overseas subsidiary. It does not change the listed company's board or operations, so the immediate stock impact is likely neutral.